VI-1121 for the Treatment Alzheimer's Disease

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VIVUS, Inc.
• Collaborator: Medpace, Inc.

Criteria

Inclusion Criteria:

• clinical diagnosis of Alzheimer's disease

• CT or MRI within 2 years prior to study

• stable dose of current Alzheimer's treatment for at least 3 months

Exclusion Criteria:

• advanced, severe, progressive or unstable disease

• history of cerebrovascular disease or myocardial infarction within 6 months